BPD Biopharmaceutical Bioprocess Development Summit with QFINITY | August 6-7, 2026
We are glad to be at the 9th BPD Biopharmaceutical Bioprocess Development Summit in Shanghai!
The summit runs August 6-7, 2026 in Shanghai – China’s benchmark event for biopharmaceutical process development, from research to commercial manufacturing. Since 2017 it has connected the entire CMC value chain; the 2025 edition drew more than 5,500 attendees and over 160 speakers. The AI FOR PHARMA Conference 2026 runs alongside it.
QFINITY on stage
Oliver Herrmann (QFINITY) and Martin Heitmann (MH Consulting & Advisory) are pleased to speak at both conferences on August 6: at the BPD Summit itself on the shift in EU GMP regulation, and at the parallel AI FOR PHARMA Conference on how adaptive AI only becomes GMP-ready under control.
Shifting the EU GMP Regulatory Paradigm – Annex 11 and Annex 22 Drafts
Oliver Herrmann (QFINITY) and Martin Heitmann (MH Consulting & Advisory)
“Global Expansion & Globalization” track. For companies expanding into European markets, the regulatory ground is shifting: the revised EU GMP Annex 11 and the new Annex 22 draft reshape how computerized systems – and, increasingly, AI – are assessed in GxP environments. The talk maps out what quality, IT, and regulatory teams need to prepare for.
Adaptive AI Without Control is Not GMP – From Potential to Controlled Biopharma
Digital Compliance Architecture for Trustworthy Adaptive AI-Enabled Systems from Process Development to GxP Manufacturing
Oliver Herrmann (QFINITY) and Martin Heitmann (MH Consulting & Advisory)
AI FOR PHARMA Conference. Adaptive AI systems change their behavior as new data comes in – exactly what makes them powerful and hard to keep in check. Without robust control, that potential never reaches GMP. The talk outlines a digital compliance architecture that keeps adaptive, AI-enabled systems trustworthy and verifiable, from process development through to GxP manufacturing.
Meet us in Shanghai – we look forward to connecting in person.
